Evidence map›Paper›PMID 42423529›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A Fentanyl-Responsive Microneedle Patch for Harm Reduction.

Penghui Zhao, Zerui Zhou, Tyler Wolter, Huanqing Niu, Yuanzhi Bian, Chixia Tian, Chun Xu, Chenming Zhang, Juhong Chen, Matthew W Buczynski and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Penghui ZhaoDepartment of Biological Systems Engineering, Virginia Tech, Blacksburg, Virginia, USA.
Zerui ZhouDepartment of Biological Systems Engineering, Virginia Tech, Blacksburg, Virginia, USA.
Tyler WolterAcademy of Integrated Science, College of Science, Virginia Tech, Blacksburg, Virginia, USA.
Huanqing NiuDepartment of Biological Systems Engineering, Virginia Tech, Blacksburg, Virginia, USA.
Yuanzhi BianDepartment of Biological Systems Engineering, Virginia Tech, Blacksburg, Virginia, USA.
Chixia TianAcademy of Integrated Science, College of Science, Virginia Tech, Blacksburg, Virginia, USA.
Chun XuSydney Dental School, The University of Sydney, Camperdown, New South Wales, Australia.
Chenming ZhangDepartment of Biological Systems Engineering, Virginia Tech, Blacksburg, Virginia, USA.
Juhong ChenDepartment of Bioengineering, University of California Riverside, Riverside, California, USA.
Matthew W BuczynskiSchool of Neuroscience, Virginia Tech, Blacksburg, Virginia, USA.
Wujin SunDepartment of Biological Systems Engineering, Virginia Tech, Blacksburg, Virginia, USA.ORCID https://orcid.org/0000-0002-3167-111X

Funding

VT BSE Startup Package
6 · The paper itself

Abstract

The efficacy of current opioid overdose interventions is fundamentally limited by their reliance on bystander detection and administration, leaving unwitnessed overdoses, a predominant cause of fatalities, unaddressed. Herein, we developed an innovative fentanyl-responsive microneedle (MN) patch (iNal patch) engineered as an autonomous harm reduction tool to dynamically release naloxone on demand in response to fentanyl levels. Specifically, the iNal patch integrates mesoporous silica nanoparticles (MSNs) loaded with naloxone. The nanoparticle surfaces are modified by fentanyl-sensitive aptamers, allowing precise and dose-dependent drug release triggered by fentanyl exposure. The engineered MN matrix composed of swellable maleated poly(vinyl alcohol) facilitates rapid skin penetration and interstitial fluid access, ensuring immediate and sustained naloxone release. From in vitro and in vivo studies, the iNal patch was demonstrated to effectively reverse fentanyl-induced opioid overdose symptoms, rapidly restore normal physiological behaviors in mice, and enable multiple responsive drug-release cycles to prevent renarcotization. This proof-of-concept MN platform establishes a new paradigm for materials-based harm reduction, offering an autonomous safety net for high-risk populations independent of human supervision.

Indexed as

Drug OverdoseFentanylHarm ReductionNaloxoneTransdermal PatchAnalgesics, OpioidAnimalsHumansMaleMiceMicroneedle Drug DeliveryNarcotic AntagonistsAnalgesics, OpioidFentanylNaloxoneNarcotic AntagonistsFentanylHarm ReductionMicroneedleNaloxoneResponsive Delivery

Identifiers

PMID42423529
PMCPMC13348650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.